InteRNA Technologies announces establishment of Scientific Advisory Board
- Jaap Verweij, MD, PhD, Professor of Medical Oncology at the Department. of Medical Oncology at Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands;
- William C. Hahn, MD, PhD, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute and Senior Associate Member at the Broad Institute of Harvard and MIT, Boston, USA;
- Allan Balmain, PhD, FRSE, Barbara Bass Bakar Distinguished Professor in Cancer Genetics at UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA;
- Graham Dixon, PhD, Sr. VP Drug Discovery, Galapagos NV, Mechelen, Belgium;
- Edwin Cuppen, PhD, scientific co-founder of InteRNA Technologies, and Professor of Genome Biology at Utrecht University, Professor of Human Genetics and head of the Research section of the Department of Medical Genetics, UMC Utrecht and staff scientist at Hubrecht Institute, Utrecht, the Netherlands;
- Eugene Berezikov, PhD, scientific co-founder of InteRNA Technologies and staff scientist at Hubrecht Institute, the Netherlands.
“We are very pleased with the formation of our SAB and feel honored to collaborate with this experienced team that is highly committed advising the Company on moving forward its research and development towards the clinic”, said Roel Schaapveld, CEO of InteRNA Technologies. “The complementary knowledge of the renowned clinicians and scientists in this team will play a significant role in our R&D programs and success of the Company.”
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.